If approved, Sovaldi could be available in the European Union in the first quarter of 2014
2 billion before rebates on Sovaldi and Harvoni
The approved indication is: " Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults (see sections 4
Treatment for: Hepatitis C Vosevi (sofosbuvir, velpatasvir and
Gilead prices the drug at $57,000 in the United Kingdom and $66,000 in Germany
The U
To make corresponding changes to the Patient Information
For The Economic Committee for Health Products (CEPS) has agreed a price of €13,667 per 28-tablet pack of Sovaldi (sofosbuvir), around €5,000 lower than the initial list price, as well as rebates on the drug's cost in cases of treatment failure
This is up from $84,000 for 12 weeks of Sovaldi, but is in line with the combined price of Sovaldi, ribavirin and interferon
“I believe sofosbuvir has the potential to transform HCV treatment in Canada as it addresses many unmet patient needs,” said Jordan Feld, MD , MPH, Staff This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities
Marketing approval applications for sofosbuvir are also pending in Australia, Canada, New Zealand, Switzerland and Turkey []
5 percent will receive the drug at Approval allows the Foster City-based company to sell Harvoni in 28 European countries; now it must negotiate the price with those nations
Vision impaired people having problems accessing certain pages of a PDF file may call (301) 796-3634 for Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults
An internal document from September 2013 reveals that Gilead’s proposed European price corridor targeted a ceiling price for Sovaldi of $64,400 per 12-week course of therapy in Germany and a Sovaldi is a drug marketed by Gilead Sciences Inc and is included in two NDAs
Today’s marketing authorization follows an accelerated assessment by the European Medicines Agency, a designation that is granted to new medicines of major public health interest, and allows for the marketing of Sovaldi in all 28 countries of the European Union (EU)
It is also approved for use in 79 countries including Australia , India , Indonesia , the Philippines , New Zealand , Canada , Egypt , Switzerland and Turkey